April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
In Vivo and In Vitro MRI of Pseudophakic Human Eyes
Author Affiliations & Notes
  • Susan A. Strenk
    MRI Research, Inc, Middleburg Heights, Ohio
  • Bosco Tjan
    Psychology, University of Southern California, Los Angeles, California
  • Liliana Werner
    Ophthalmology, University of Utah/Moran Eye Center, Salt Lake City, Utah
  • Nick Mamalis
    Ophthalmology, University of Utah/Moran Eye Center, Salt Lake City, Utah
  • Lawrence M. Strenk
    MRI Research, Inc, Middleburg Heights, Ohio
  • Footnotes
    Commercial Relationships  Susan A. Strenk, Alcon (F), MRI Research, Inc (I, E); Bosco Tjan, MRI Research, Inc (C); Liliana Werner, MRI Research, Inc (C); Nick Mamalis, MRI Research, Inc (C); Lawrence M. Strenk, Alcon (F), MRI Research, Inc (I, E)
  • Footnotes
    Support  NIH Grant EY015655, NIH Grant EY018518
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4728. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Susan A. Strenk, Bosco Tjan, Liliana Werner, Nick Mamalis, Lawrence M. Strenk; In Vivo and In Vitro MRI of Pseudophakic Human Eyes. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4728.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Complications of new intraocular lens (IOL) designs are often not discovered until years after their introduction and often linked to Soemmering’s ring (SR), a growth that develops to some extent after most cataract surgeries. SR abundance is directly related to the post operative period and inversely to patient age and care taken in cortical clean-up. IOL design also plays a significant role. MRI is not impeded by the iris or optical distortions and has the unique ability to visualize the entire IOL and surrounding SR.

Methods: : Donor eyes (N=100, ages 60-99) were imaged either at 1.5T (General Electric) or 3T (Siemens) using custom rf coils (MRI Research) and T1 weighting. Several donor eyes underwent gross and pathological evaluation in order to characterize SR and validate that the image contrast at 3T was comparable to 1.5T. Cataract patients (N=14, ages 69-87) were imaged at 3T to allow shorter scans, which is an important consideration for geriatric volunteers. The location, size, and nature of SR were measured with MRI, gross and histopathological analysis.

Results: : MRI revealed up to three distinct layers of SR: a dark inner-area; a concentric gray layer; and a concentric bright, outer-most layer. Gross analysis confirmed the presence of SR and pathological analysis revealed the dark areas to be calcification; the gray areas to be dense, irregular cortical material; and the bright concentric outmost layer to be normal cortical material. SR appears to reach its maximum size within several years post surgery; after which time it may become bi-lamellar, and, ultimately, tri-lamellar as the innermost layer calcifies. In-vivo images were at a lower in plane resolution (156 vs 39 microns) but were otherwise consistent with in-vitro findings.

Conclusions: : This study cross-validates MRI of cataract patients with MRI of donor eyes, on which gross and histopathological analysis have been conducted. Accommodating-IOLs may be implanted in younger people with whom SR is likely to develop more abundantly and thus potentially lead to more complications. Additionally, A-IOLs are likely to be in place for longer periods of time, thus allowing multi-lamellar SR to develop; the resulting calcifications may limit haptic movement. Longitudinal in vivo MRI studies of cataract patients provide an opportunity to obtain timely feedback on SR development in newly introduced IOLs.

Keywords: cataract • intraocular lens • treatment outcomes of cataract surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×